Want to see GB:HEMO full AI Analyst Report?
HEMO Stock Chart & Stats
556.00 p
21.00 p(2.89%)
At close: 4:00 PM EDT
556.00 p
21.00 p(2.89%)
Day’s Range― - ―
52-Week Range356.00 p - 1,800.00 p
Previous CloseN/A
Volume7.73K
Average Volume (3M)17.02K
Market Cap
£33.79M
Enterprise Value53.32M
Total Cash (Recent Filing)£1.59M
Total Debt (Recent Filing)£2.00M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding6,896,786
10 Day Avg. Volume26,399
30 Day Avg. Volume17,018
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)21.26
Price to Sales (P/S)0.00
P/FCF Ratio-7.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt ReductionReducing total debt provides some improvement in financial flexibility despite the company’s broader leverage risk. Lower obligations may reduce future financing pressure and interest burden, helping preserve capital for research programs while management works toward commercial development.
Improved Operating Cash BurnThe reduction in operating cash outflow indicates some progress in controlling cash consumption, even though the company remains loss-making and cash-flow negative. If sustained, tighter spending could extend funding runway and support continued development of therapeutic candidates.
Specialized Hematology FocusA focused emphasis on blood-forming stem cells and hematology/oncology gives the company a defined therapeutic identity rather than a broad, unfocused research scope. Concentrating resources in these areas may support deeper scientific expertise and clearer development priorities.
Bears Say
Pre-Revenue ProfileThe absence of revenue confirms that the business has not yet established a commercial income stream. Continued dependence on research-stage development leaves future funding and value creation reliant on advancing candidates toward approval, partnerships, or eventual product sales.
Widening Net LossesWidening losses indicate that current operating costs are not yet supported by revenue and that profitability remains distant. Persistent deterioration can consume equity, increase reliance on external capital, and reduce the company’s ability to fund its pipeline without dilution or additional debt.
Leverage And Shrinking EquityDebt exceeding equity leaves a limited balance-sheet cushion for a loss-making biotechnology company. The substantial decline in equity weakens financial resilience, while continued losses could further constrain borrowing capacity and make future capital raising more important for ongoing operations.
HemoGenyx Pharmaceuticals Plc News
HEMO FAQ
What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?
HemoGenyx Pharmaceuticals Plc lowest share price was 356.00 p and its highest was 1800.00 p in the past 12 months.
What is HemoGenyx Pharmaceuticals Plc’s market cap?
HemoGenyx Pharmaceuticals Plc’s market cap is £33.79M.
When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?
HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date is Sep 24, 2026 which is in 13 days.
How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?
HemoGenyx Pharmaceuticals Plc released its earnings results on Apr 30, 2026. The company reported -0.787 p earnings per share for the quarter.
Is HemoGenyx Pharmaceuticals Plc overvalued?
According to Wall Street analysts HemoGenyx Pharmaceuticals Plc’s price is currently Overvalued.
Does HemoGenyx Pharmaceuticals Plc pay dividends?
HemoGenyx Pharmaceuticals Plc does not currently pay dividends.
What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?
HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?
HemoGenyx Pharmaceuticals Plc has 6,896,786 shares outstanding.
What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?
HemoGenyx Pharmaceuticals Plc reported an EPS of -0.787 p in its last earnings report. Following the earnings report the stock price went down -0.735%.
Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in GB:HEMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HemoGenyx Pharmaceuticals Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.85%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions for the bone marrow and hematopoietic stem cell (BM/HSC) transplant sector. Key developments include a CDX bi-specific antibody, engineered to target challenging conditions such as relapsed/refractory acute myeloid leukaemia (R/R AML), specific forms of acute lymphoblastic leukaemia, and myelodysplastic syndrome, aiming to replace traditional chemotherapy or radiation for transplant conditioning. Also under development is HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to effectively identify and destroy human acute myeloid leukaemia cells in laboratory and in vivo settings. Additionally, the company is advancing Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapeutic specifically for BM/HSC transplant procedures. Founded in 2012, Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.
Technical Analysis
ImmuPharma
―
Open Orphan Plc
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―